Quarterly report pursuant to Section 13 or 15(d)

Note 8 - Stockholders' Equity (Tables)

v3.23.3
Note 8 - Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2023
Notes Tables  
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
                   

Weighted

         
                   

Average

         
   

Number

   

Weighted

   

Remaining

   

Aggregate

 
   

of Options

   

Average

   

Contractual

   

Intrinsic Value

 
   

(in thousands)

   

Exercise Price

   

Term (years)

   

(in thousands)

 

Outstanding at December 31, 2022

        $           $  

Granted

    1,685,000     $ 1.14       10.0     $  

Exercised

        $           $  

Cancelled/forfeited

        $           $  

Expired

        $           $  

Outstanding at Balance at September 30, 2023

    1,685,000     $ 1.14       9.7     $  

Expected to vest

    1,422,500     $ 1.14       9.7     $  

Exercisable

    262,500     $ 1.14       9.7     $  
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
   

Nine Months Ended September 30,

 
   

2023

   

2022

 

Volatility

    124.9 - 125.7 %     %

Expected term (in years)

    5.8 - 5.9        

Risk-free rate

    4.1 %     %

Expected dividend yield

    %     %
Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]
   

Number of

   

Weighted

 
   

Units and

   

Average Grant

 
   

Awards

   

Date Fair Value

 
   

(in thousands)

         

Unvested balance at December 31, 2022

    13,137     $ 12.08  

Unvested balance at March 31, 2023

    13,137     $ 12.08  

Granted

    85,000       1.14  

Unvested balance at June 30, 2023

    98,137     $ 2.60  

Unvested balance at September 30, 2023

    98,137     $ 2.60  
Share-Based Payment Arrangement, Cost by Plan [Table Text Block]
   

For the three months ended

   

For the nine months ended

 
   

September 30,

   

September 30,

   

September 30,

   

September 30,

 
   

2023

   

2022

   

2023

   

2022

 

Research and development

  $ 144     $ 8     $ 150     $ 297  

General and administrative

    417       17       449       340  

Total stock-based compensation expense

  $ 561     $ 25     $ 599     $ 637  
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]
           

Weighted

         
           

Average

   

Aggregate

 
           

Exercise

   

Intrinsic Value

 
   

Warrants

   

Price

   

(in thousands)

 

Outstanding, December 31, 2022

    4,137,916     $ 3.30     $ 1  

Granted

    3,432,598       0.88        

Exercised

    (400,083 )            

Outstanding, March 31, 2023

    7,170,431     $ 1.32       1,272  

Exercised

    (1,092,299 )            

Outstanding, June 30, 2023

    6,078,132     $ 1.55     $ 1  

Outstanding, September 30, 2023

    6,078,132     $ 1.55     $ 1